Search clinical trials for: MDT-2111 TAVI 23 mm

Total 15 results

Medtronic Cardiovascular

Completed

Clinical Evaluation of MDT-2111 in Subjects With Small Aortic Annuli and Symptomatic Severe Aortic Stenosis

Aortic Valve Stenosis

Japan
Medtronic Cardiovascular

Completed

Clinical Evaluation of MDT-2111 in Subjects With Symptomatic Severe Aortic Stenosis

Aortic Valve Stenosis

Japan
Institut für Pharmakologie und Präventive Medizin
Edwards Lifesciences

Completed

Validation of the "TASQ" in Patients Undergoing SAVR or TF-TAVI (TASQ)

Aortic Valve Stenosis

Austria, Canada, France, Germany, Italy, Spain, United Kingdom
Merrimack Pharmaceuticals

Completed

A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers (Monotherapy)

Metastatic Breast Cancer | Her2 Amplified Solid Tumors

United States
Medtronic Vascular

Completed

Renal Denervation by MDT-2211 System in Patients With Uncontrolled Hypertension (HTN-J)

Uncontrolled Hypertension

Japan
Merrimack Pharmaceuticals

Completed

A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

HER-2 Gene Amplification

United States
Medtronic Endovascular

Completed

MDT-2113 Drug-Eluting Balloon vs. Standard PTA for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery (MDT-2113 SFA)

Popliteal Artery Stenosis | Popliteal Artery Occlusion | Femoral Artery Occlusion | Femoral Artery Stenosis

Japan
Merrimack Pharmaceuticals

Completed

MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer

Breast Neoplasms

United States
Pearl Therapeutics, Inc.

Completed

Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease (COPD)

United States
Merrimack Pharmaceuticals

Terminated

A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

Stomach Cancer | Gastroesophageal Junction Cancer | HER-2 Gene Amplification | Esophagus Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma | Advanced Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
National Cancer Institute (NCI)

Completed

Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer

Recurrent Prostate Carcinoma | Stage IV Prostate Cancer AJCC v7

United States
National Cancer Institute (NCI)

Recruiting

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7

United States
IUATLD, Inc
Medical Research Council; Institute of Tropical Medicine, Belgium; Liverpool... and other collaborators

Completed

The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB (STREAM)

MDR-TB

Ethiopia, Georgia, India, Moldova, Republic of, Mongolia, South Africa, Uganda
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma

Recurrent Neuroblastoma | Refractory Neuroblastoma | High Risk Neuroblastoma

United States, Canada, Puerto Rico, Australia, New Zealand

Search clinical trials for: MDT-2111 TAVI 23 mm

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Denmark

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations